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Congenital erythropoietic porphyria (CEP) is a recessive autosomal disorder characterized by a deficiency in uroporphyrinogen III
synthase (UROS), the fourth enzyme of the heme biosynthetic pathway. The severity of the disease, the lack of specific treatment except
for allogeneic bone marrow transplantation, and the knowledge of the molecular lesions are strong arguments for gene therapy. An
animal model of CEP has been designed to evaluate the feasibility of retroviral gene transfer in hematopoietic stem cells. We have
previously demonstrated that the knockout of the Uros gene is lethal in mice (Urosdel model). This work describes the achievement of a
knock-in model, which reproduces a mutation of the UROS gene responsible for a severe UROS deficiency in humans (P248Q missense
mutant). Homozygous mice display erythrodontia, moderate photosensitivity, hepatosplenomegaly, and hemolytic anemia. Uroporphyrin
(99% type I isomer) accumulates in urine. Total porphyrins are increased in erythrocytes and feces, while Uros enzymatic activity is
below 1% of the normal level in the different tissues analyzed. These pathological findings closely mimic the CEP disease in humans
and demonstrate that the Urosmut248 mouse represents a suitable model of the human disease for pathophysiological, pharmaceutical, and
therapeutic purposes.
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Congenital erythropoietic porphyria (CEP) is a rare disease
that is inherited as an autosomal recessive trait and charac-
terized biochemically by a massive porphyrinuria resulting
from the accumulation in the bone marrow, peripheral blood,
and other organs of large amounts of predominantly type I
porphyrins. The diagnosis can be confirmed by the demon-
stration of a profound deficiency of uroporphyrinogen III
synthase (UROS; EC 4.2.1.75) enzymatic activity in erythro-
cytes and other tissues [1,2]. The determination of the
nucleotide sequence of the cDNA encoding UROS [3] has0888-7543/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Spain.made possible the study of the molecular lesions responsible
for the disease [2,4–14]. In most of the patients, the prognosis
is poor and death occurs in early adult life. However, some
variability exists in the expression of the disease, varying
from extremely severe neonatal to mild late-onset forms
[1,2,11,12].
Current available treatments are only symptomatic and
unsatisfactory. Because the predominant site of metabolic
expression of the disease is the erythropoietic system, bone
marrow transplantation represents a curative treatment for
patients with severe phenotypes, when a HLA-compatible donor
is available [1,2,15]. The development of a mouse model of the
disease will permit ex vivo gene therapy experiments on the
entire animal.
The data shown in this report demonstrate that the
Urosmut248 knock-in mouse represents a valuable model of
the human UROS deficiency disease (CEP).06) 84 – 92
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Targeting of the Uros gene in ES cells and generation of
transgenic mutant mice
The targeting construct represents 6.22 kb of mouse
genomic DNA and contains the last two exons of the Uros
gene (exons 9 and 10). Fig. 1 shows the targeting strategy: the
homologous recombination between the targeted locus and the
targeting construct leads to a modified gene that contains the
positively selectable gene neor, which replaces a 0.9-kb piece
of the 9th intron of the Uros gene. The P248Q missense
mutation, encoded by a CCA Y CAA change, is located inFig. 1. (A) Targeting construct and (B, C) Uros gene analysis in ES cells. The t
Parental genomic locus containing the 9th and 10th exons of the mouse Uros
TK in the replacement vector. Bottom: Resulting targeted locus. The region of h
positions of the probes used in Southern blot analyses are shown under the targ
on the corresponding gene fragments. Homologous recombination was assessed
digests, probes A and B each recognized two bands in homologous recomb
corresponding to the targeted and normal allele, respectively. When random inte
two bands, a common (20 kb) and a variable sized band, due to random integr
the normal allele at the targeted locus). A typical profile of the PCR fragments
ES cells, two PCR products were obtained, 0.9 and 1.1 kb, corresponding to
genotyping on mouse tail biopsies.exon 10. The targeting construct contains a copy of the
negatively selectable marker, herpes simplex thymidine kinase
gene (HS-TK), which allows the use of a positive–negative
selection of homologous recombinant ES clones. Two hundred
five double-resistant ES clones were successfully amplified.
The screening for the targeting event (Fig. 1) included PCR
with different sets of primers along and outside the targeted
locus, Southern blot, sequencing of exon 10, and Uros
enzymatic assay. Five independent ES clones were character-
ized as homologous recombinants by PCR and Southern blot
but only two contained the P248Q mutation and showed a 50%
decrease in Uros enzymatic activity. After blastocyst reimplan-
tations, 10 viable chimeras were obtained and 6 gave germ-lineargeting construct used to electroporate ES cells is shown in panel A. Top:
gene. Middle: Targeting construct including the selective markers neo\ and
omology is shown by crossing lines on each side of the neo cassette. The
eted construct. The primers used in PCR assays are shown by small arrows
by Southern blot analysis in ES cells, as shown in panel B. In EcoRI
inant ES cells, 6.8 and 20 kb (probe A) or 16 and 20 kb (probe B),
gration occurred, probe A gave a single band (20 kb), while probe B gave
ation (the EcoRI restriction site is located in the neo cassette and absent in
generated with the (1, 2) primer set is shown in panel C. In heterozygous
the normal and the neo allele, respectively. The same PCR was used for
Table 1
Comparison of liver and spleen weight with reference to body weight (BW) in
6-month-old mice
Genotype n BW Liver Spleen Liver/BW Spleen/BW
(g) (g) (g) (%) (%)
Mut/Mut 5 27.8 T 5.1 2.01 T 0.39 0.77 T 0.18 7.26 T 0.94 2.9 T 1.08
pa NS <0.005 <0.005 <0.005 <0.005
Mut/N 6 29.2 T 5.5 1.39 T 0.39 0.12 T 0.12 4.66 T 0.86 0.43 T 0.12
pb NS NS NS NS NS
N/N 6 30.8 T 4.5 1.34 T 0.26 0.10 T 0.16 4.40 T 0.82 0.30 T 0.11
a Mut/Mut vs N/N.
b Mut/N vs N/N.
C. Ged et al. / Genomics 87 (2006) 84–9286transmission after breeding with wild-type mice. Finally, 17
heterozygous mice out of 63 births were characterized. The
intercrosses between these heterozygous mice gave 59 births
from 16 litters. The following frequencies were observed:
18.6% (11/59), 44.1% (26/59), and 37.3% (22/59) in theFig. 2. Clinical features of the mouse model. Physical examination of homozygous m
erythrodontia, (B) discolored fingers due to anemia, (C) red-colored urine, and (D) li
reddish-brown color on daylight exposure. (H) Blood spread showed that red blood c
mainly discolored (hypochromia). (I) Microscopic examination under UV light eviUrosP248Q/P248Q (Mut/Mut), UrosP248Q/N (Mut/N), and UrosN/N
(N/N) genotypes, respectively.
Clinical features of the model
Heterozygous mice (Mut/N) appeared normal. Homozygous
mice (Mut/Mut) were hypotrophic at birth and recognizable by
producing red urine and showing erythrodontia in the first
weeks of life. Later on, no difference in body weight was noted
in homozygous mice compared to normal or heterozygous
siblings (Table 1). Photosensitivity lesions of the ears and the
back of the neck were observed in homozygous mice after
several months of life. The examination after laparotomy
showed enlarged liver and spleen and a brownish coloration of
these organs, due to the accumulation of porphyrins. Bones
were abnormally fragile and remained intensely colored after
bone marrow aspiration (Fig. 2).ice (right side of each panel) compared to normal litters (left side) showed (A)
ver and (E) spleen enlargement. Liver, spleen, (F) bones, and (G) kidneys had a
ells varied in size (anisocytosis) and pigment content (polychromasia) and were
denced numerous fluorocytes.
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Porphyrin studies demonstrated a massive accumulation of
total porphyrins in blood, urine, and feces (Table 2). In UROS
deficiency, the majority of hydroxymethylbilane (linear tetra-
pyrrole) is converted into uroporphyrinogen I by a spontane-
ous cyclization (Fig. 3). In urine, the accumulation of
uroporphyrin consisted in 99.5% of the type I isomer.
Uroporphyrinogen I is partly converted into coproporphyrino-
gen I by the next enzyme of the heme pathway (uroporphyr-
inogen decarboxylase), and low amounts of intermediates
harboring seven, six, or five carboxylic acid groups are found
in the urine (Table 2). Hepatic (20.76 T 5.66 nmol/g protein)
and splenic (17.78 T 11.86) porphyrin accumulation increased
15- and 50-fold, respectively, in homozygous animals com-
pared to normal porphyrin levels (1.37 T 1.1 and 0.36 T 0.19).
In heterozygous animals, porphyrin levels were similar to the
normal levels in all tissues examined.
Uros enzymatic activity in erythrocytes was about 50%
(8.19 T 2.92 U/mg protein) and less than 1% (<0.1 U/mg) of
the control level (12.51 T 2.92 U/mg) in heterozygous and
homozygous mice, respectively.
Hepatic parameters showed normal total bilirubin and
alkaline phosphatase levels, and a slight increase in transam-
inase levels (two- to fourfold) in homozygous animals.
Hematological data are shown in Table 3. Homozygous
mice had a severe microcytic and hypochromic anemia. The
hemolytic process was evidenced by the high reticulocyte
count and the presence of numerous erythroblasts with
poikilocytosis and anisochromia, on microscopic examination.
Flow-cytometric analysis of peripheral red blood cells showed
that 10 to 30% of cells presented with abnormal porphyrin-
mediated fluorescence (Fig. 4). Remarkably, the fluorocytes
were mostly in the reticulocyte fraction, as characterized by
orange thiazol dye.Table 2
Porphyrin accumulation in red blood cells, urine, and feces
Mut/Mut (n = 5) Mut/N (n = 6) N/N (n = 6)
Red blood cells
(pmol/mg Hb)
72.06 T 44.96 3.77 T 0.47 3.95 T 1.6
Urine
Total porphyrins
(Amol/L)
498 T 328 <0.5 <0.5
Uroporphyrin (%) 88.6 T 2.3 ND ND
Heptacarboxylic
porphyrin (%)
3.1 T 1.0 ND ND
Hexacarboxylic
porphyrin (%)
1.0 T 0.1 ND ND
Pentacarboxylic
porphyrin (%)
2.7 T 0.3 ND ND
Coproporphyrin (%) 4.7 T 1.4 ND ND
Uroporphyrin I (%) 99.5 ND <20
Uroporphyrin III (%) 0.5 ND >80
Fecal porphyrins (nmol/g) 185 T 67 <10 <10Histologic studies
Histological examination of bone marrow and spleen
revealed an increase in erythroid precursor cells that paralleled
the enlargement of the splenic red pulp. In the liver, several
erythroid clusters were also noted and were associated with a
mild centrilobular steatosis. Multifocal accumulation of a
brown pigment was observed mainly in Kupffer cells and
corresponded to iron deposits as attested by Perls staining.
In kidney, part of the glomeruli and tubules were filled by an
eosinophilic material, which tended to enlarge the lumens.
Again, a cortical brown pigmentation due to iron accumulation
in the epithelial layer of the proximal convoluted tubules was
evidenced by Perls staining (Fig. 5). Iron deposits in all these
organs are probably linked to a sustained hemolytic process.
Discussion
In a previous work, we have demonstrated that homozygous
Urosdel embryos are nonviable from the earliest stage of
development, i.e., blastocyst [16]. The finding that the
disruption of the Uros gene is fully lethal is not surprising
since the Uros enzyme contributes to the biosynthesis of heme,
which is an essential compound in any mammalian cell.
Two mouse knockout models of porphyria have been
previously described: acute intermittent porphyria (AIP) and
familial porphyria cutanea tarda (f-PCT), due to porphobilino-
gen deaminase and uroporphyrinogen decarboxylase (UROD)
deficiency, respectively [17,18]. In both models, the disruption
of the gene was lethal in homozygous offspring. However, the
genetic backgrounds are different; the corresponding human
diseases are inherited in an autosomal dominant way and other
genetic or environmental factors are necessary for the expression
of the disease. In the mouse AIP model, neurological abnor-
malities were observed after phenobarbital administration in
compound heterozygous animals. The animal model was
designed mainly for a pathophysiological purpose [19]. In the
mouse f-PCT model, Urod+/ mice did not accumulate hepatic
porphyrins, while Urod+//Hfe/ mice developed a porphyric
phenotype by 14 weeks of age, due to the addition of the Hfe/
mutant modifier gene [18].
In CEP patients, the correlation between the phenotype and
the genotype is well established [2]. The mutations responsible
for the disease consist in nonsense and missense mutations,
insertions, splicing defects, and base changes in the promoter
of the UROS gene. No large deletion has been observed and a
significant percentage of residual activity is always maintained.
In this work, the knock-in strategy was chosen to obtain a
viable mutant phenotype in mice. The P248Qmissense mutation
has been shown to cause a severe phenotype in homozygous
patients and a profound enzyme deficiency [2]. The structure of
the UROS gene is very similar in human and mouse: the same
exon–intron structure, the same size of coding sequences, and a
single nucleotide change reproduced the mutation in the mouse
sequence as well as in humans [20–23]. The expression of a
P248Q mutant mouse Uros cDNA analyzed in a prokaryotic
system (Escherichia coli) showed that the enzymatic activity of
Fig. 3. Enzyme deficiency in CEP. (A) The enzyme deficiency present in CEP leads to the accumulation of uroporphyrin I and coproporphyrin I.
Coproporphyrinogen I is not a substrate for the subsequent reactions of heme synthesis. Uro- and coproporphyrinogen I are oxidized into porphyrins I, accumulate in
tissues, and are excreted in urine and feces. (B) In the presence of uroporphyrinogen III synthase (2), hydroxymethylbilane (HMB) is converted into
uroporphyrinogen III (UROgen III). In the absence of the enzyme (1), HMB is converted into uroporphyrinogen I (UROgen I). Uroporphyrinogen decarboxylase (3)
catalyzes the transformation of UROgen I and III into COPROgen I and III, respectively.
C. Ged et al. / Genomics 87 (2006) 84–9288the resulting mutant Uros protein was 1% of the level of the
corresponding normal Uros cDNA. This finding was in
agreement with previous results in the same prokaryotic
expression system using human UROS cDNA [11].
As expected, in theUrosmut248 knock-inmodel, heterozygous
mice appeared normal, while homozygous mice had a typical
porphyric phenotype as can be seen from the biochemical andTable 3
Hematological parameters in 6-month-old mice
Mut/Mut (n = 5) Mut/N (n = 6) N/N (n = 6)
Hb (g/dl) 7.94 T 0.46 13.24 T 0.84 13.21 T 1.17
RBC (1012/L) 6.35 T 0.95 8.5 T 0.81 8.49 T 0.73
MCV (fl) 39.52 T 2.05 48.57 T 3.42 48.13 T 2.03
MCH (pg) 12.78 T 1.74 15.63 T 0.83 15.58 T 0.70
MCHC (g/dl) 31.92 T 3.25 32.22 T 0.69 32.38 T 0.73
Platelets (109/L) 524.98 T 490.16 565.17 T 275.13 535.67 T 248.07
Reticulocytes (%) 29.72 T 6.41 5 5
Fluorocytes (%) 20.90 T 7.02 <0.5 <0.5hematological data. A dramatic increase in porphyrin level was
found in red blood cells, urine, and feces, a typical feature of a
severe CEP form in humans. Chronic anemia, due to excessive
hemolysis, was detected on the first blood examination and had
no influence on mouse development or behavior. The presence
of numerous fluorocytes among the reticulocyte fraction of red
blood cells was a typical hallmark of the disease and a
convenient diagnosis test in this mouse model. The development
of photosensitivity lesions was delayed and well tolerated
without evident infected and scarring lesions.
The availability of a mouse model of UROS deficiency
represents a powerful tool for gene regulation studies,
pathophysiological analyses, and therapeutic purposes [24].
The understanding of UROS gene regulation is partial. In
mouse and human, tissue-specific expression is ensured by two
distinct promoter regions: erythroid and housekeeping se-
quences have been described in erythroid and nonerythroid
cells [22,23]. In the recent description of a large CEP family,
different siblings had severe clinical manifestations, while one
Fig. 4. Flow-cytometric analysis of fluorocytes and reticulocytes. (A and B) Selection of the red blood cell population by gating with side scatter (SSC-height) and
forward scatter (FSC-height) in normal (A) and homozygous mice (B). (C and D) Histogram drawings of the reticulocyte population in normal (C) and homozygous
mice (D). (E and F) Analysis of the reticulocyte fraction by orange thiazol labeling (x axis, FL-1 channel) and of the fluorocyte fraction by red fluorescence ( y axis,
FL-3 channel) in normal (E) and homozygous mice (F). Fluorocytes are mainly in the reticulocyte fraction.
C. Ged et al. / Genomics 87 (2006) 84–92 89homozygous mutant sibling was clinically healthy [14]. This
observation led to the hypothesis of a putative modifier gene
responsible for the phenotypic variability. The same hypothesis
has recently been documented in a mouse model of erythropoi-
etic protoporphyria, the Fechm1Pas/m1Pas mouse, obtained by
chemical mutagenesis [25]. The study performed on three con-
genic strains provides strong evidence for an independent ge-
netic control of bone marrow contribution to porphyrin
overproduction [26]. Our mouse model of CEP is a valuable
tool to investigate the phenotypic variability inUROSdeficiency.
A second field of interest is the possibility of ex vivo and in
vivo gene therapy experiments. We and others have documented
a sufficient in vitro gene transfer rate and metabolic correction in
different CEP deficient cells to indicate that the disease is a good
candidate for treatment by gene therapy in hematopoietic stem
cells [27–30]. Experimental gene therapy has proven successfulin the Fechm1Pas/m1Pas mouse [31–33]. Our latest results
demonstrated that correction and in vivo expansion of deficient
hematopoietic stem/progenitor cells can be achieved by a dual
gene therapy involving the therapeutic gene and the methylgua-
nine-DNA-methyltransferase-mediated selection system [34].
The recently developed lentivectors will be tested for gene
transfer experiments in our mouse model of CEP as a last step
before a gene therapy proposal in humans.Materials and methods
Construction of the targeting vector
The P248Q missense mutation was introduced by site-directed muta-
genesis in a 1.7-kb BamHI genomic fragment that contains exon 9. A
single base change (C Y A) was created by using the Gene Editor Site
Fig. 5. Histologic analyses of liver, spleen, and kidneys. Normal liver, spleen, and kidneys are shown on the left of each slide. (A–C) Liver histology showed
steatosis (gray arrowheads), clusters of erythroid cells in the sinusoids (black arrowheads), and pigment accumulation (dotted circles) due to iron deposits. (D) In
spleen, the red pulp is enlarged and filled by erythroid precursor cells at a small magnifying scale; (E) iron deposits were intense in homozygous animals, seen by
Perls staining. (F) Kidney analyses showed glomerular and tubular accumulation of a hyaline material (black arrows). (H, G) Perls staining identified iron deposits
(black arrows) which predominate in the proximal convoluted tubules of the kidney_ s cortex. 
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into pBluescript plasmid (Clontech, France). The targeting construct
prepared to obtain the Urosdel KO model [16] was modified as follows:
the 1.7-kb mutant fragment was cloned at XhoI restriction sites after partial
filling to obtain compatible ends with BamHI in the KO construct; the new
genomic fragment replaced the previously deleted one (the previous deletion
removed the 3V moiety of exon 9 and 0.8 kb of the adjacent intron). The
targeting vector contained the neo expression cassette from pMC1Neo
plasmid and the HS-TK cassette from pKSHT87S plasmid as previously
described [16].
Targeted disruption of the Uros gene in ES cells
H1ES cells were cultured on inactivated embryonic fibroblasts in DMEM
supplemented with leukemia inhibitory factor by standard methods [35,36].
The construct was electroporated into UrosN/N cells to generate UrosMut/N cell
lines: 10 Ag of the linearized targeting vector was electroporated into 107 H1ES
cells at room temperature using a Gene Pulser II system (Bio-Rad, France). The
selection with G418 (150 Ag/ml) and ganciclovir (2 Amol/L) was maintained
for 10 days. Double-resistant colonies were picked, expanded, and analyzed for
the presence of the recombination event by Southern blot, PCR, and sequencing
of the mutant exon. Chromosomal distribution was checked by karyotypic
analysis.
Generation of transgenic mice
Chimeric mice were generated by microinjection of homologous
recombinant ES cells into 129/SV blastocysts, which were implanted into
the uterine horn of pseudopregnant foster mothers. Chimeras were mated
with C57BL/6 wild-type females to facilitate the analysis of the germ-line
transmission from coat color. The offspring were analyzed for the presenceof the mutant UrosP248Q allele, and the first heterozygous animals were
interbred to generate homozygous Mut/Mut mice. These animals had a
mixed 129/SV–C57BL/6 genetic background. Animals were maintained on
a 12-h light/dark cycle and had free access to food and water. All procedures
involving animals were in accordance with the guidelines for humane care of
laboratory animals.
Uros gene analysis in ES cells and tail biopsies
DNA was prepared from ES cells and tail biopsies by lysis followed
by phenol–chloroform extraction. In Southern blot analyses, 10 Ag of
genomic DNA was digested with EcoRI enzyme, size-fractionated by
electrophoresis, and successively hybridized with two 32P-labeled probes:
probe A is a 1.5-kb SacI genomic fragment located on the 5V side of the
targeted locus in the 8th intron of the mouse Uros gene; probe B is a 1.3-
kb HindIII genomic fragment containing the 10th exon of the mouse Uros
gene (Fig. 1).
Three primer sets (1/2, 3/4, 5/6) were used for PCR analyses as shown by the
arrows in Fig. 1. Primers 1 and 2 are located on each side of the neo cassette. The
size of the amplified fragment differs in the normal and the mutant allele, 0.9 and
1.1 kb, respectively. Primer sequences are (1) 5V-CTTATGCTAGTCT-
GGTTGTG-3V and (2) 5V-GCTCAGGTCAGAAGTCACTC-3V. Amplification
with primers 3 and 4 demonstrates the targeting event: the 1.6-kb fragment
observed is specific for the targeted locus. Primer sequences are (3) 5V-
GGTTCTGTCATTTCCAGCCA-3V and (4) 5V-AGGCTTTTTGCTTCC-
TCTTG-3V. Primers 5 and 6 are located at the 3V end of the neo cassette and
the 3V end of the 10th exon of the mouse Uros gene, respectively. The
corresponding 0.9-kb fragment, observed in the mutant allele, was sequenced to
check for the presence of the P248Q mutation. Primer sequences are (5) 5V-
CCTGACGAGTTCTTCTGAGG-3V and (6) 5V-TCAGCAACAGTGGTTT-
GGCT-3V.
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PCR analyses. PCR products were purified on Qiaquick columns (Qiagen,
France) before direct sequencing using the BigDye Terminator Cycle Sequenc-
ing kit on the ABI377 automated sequencer (Applied Biosystems, France).
Biochemical and hematological measurements
Blood was collected by puncture of the orbital sinus. The usual biochemical
parameters, total bilirubin, transaminases, and alkaline phosphatases, were
measured using a CX7 (Beckman Coulter France SA, Villepinte, France).
Hematological parameters were measured in a Coulter counter (Beckman
Coulter). Porphyrin levels in blood and organs were determined spectro-
fluorimetrically using a Hitachi F-4500 fluorescence spectrophotometer (Braun
Sciencetec, France) [37]. Urinary and fecal porphyrin concentrations were
analyzed by spectrophotometry after solvent extraction. The separation and the
quantification of the different porphyrins and the uroporphyrin isomers was
done by reversed-phase HPLC [38]. Uroporphyrinogen III synthase activity
was determined by an enzyme-coupled assay as described previously [28].
One unit was defined as the amount of enzyme that formed 1 nmol of
uroporphyrinogen III per hour at 37-C.
Flow-cytometric analysis
Analyses of porphyrin-accumulating cells in peripheral blood and bone
marrow were performed with a FACS Calibur (BD Biosciences, Le Pont de
Claix, France). Porphyrin fluorescence was detected in the FL-3 channel.
Reticulocytes were labeled with orange thiazol and counted in the FL-1
channel.
Histology
Liver, spleen, and kidneys were examined after formaldehyde fixation,
paraffin embedding, and different stainings: hematein–eosine–safran, Perls,
and Schiff periodic acid. Blood and bone marrow cell spreads were analyzed by
microscopic fluorescence and direct microscopy after May–Grundwald–
Giemsa staining.
Statistical analyses
Student_s paired t tests were used for comparison between heterozygous,
homozygous, and control mice.
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